Annovis Bio, Inc.
ANVS
$1.57
-$0.07-4.27%
NYSE
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.25% | -14.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 53.50% | -43.48% | |||
| Operating Income | -53.50% | 43.48% | |||
| Income Before Tax | 53.60% | -151.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 53.60% | -151.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.60% | -151.74% | |||
| EBIT | -53.50% | 43.48% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 56.36% | -119.37% | |||
| Normalized Basic EPS | 56.35% | -119.35% | |||
| EPS Diluted | 50.94% | -119.37% | |||
| Normalized Diluted EPS | 56.35% | -119.35% | |||
| Average Basic Shares Outstanding | 6.31% | 14.75% | |||
| Average Diluted Shares Outstanding | 6.31% | 14.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||